Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

计划入组 23,670 人 · 首次发布于 2021 年 5 月 27 日

Study of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older

计划入组 21,046 人

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

计划入组 3,159 人 · 首次发布于 2021 年 2 月 21 日

A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

计划入组 1,800 人 · 首次发布于 2022 年 4 月 12 日

A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years

首次发布于 2022 年 4 月 4 日

VAT00008: A parallel-group, Phase III, multi-stage, modified double-blind, Placebo-Controlled, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent- CoV2 preS dTM-AS03 (D614) and bivalent CoV2 preS dTM-AS03 (D614 + B.1.351)) for prevention against COVID-19 in adults 18 years of age and older.

A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines

计划入组 600 人 · 首次发布于 2023 年 7 月 6 日

Clinical Trial of Recombinant Pneumococcal Protein Vaccine

计划入组 60 人 · 首次发布于 2022 年 11 月 21 日

Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines

计划入组 41,128 人

A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine

计划入组 180 人 · 首次发布于 2026 年 3 月 27 日